Perelman School of Medicine: Fewer Steroids No Plasma Exchange Change in Treatment for Vasculitis
February 13, 2020
February 13, 2020
PHILADELPHIA, Pennsylvania, Feb. 13 [TNSmedicalresearch] -- The University of Pennsylvania's Perelman School of Medicine issued the following news release on Feb. 12:
* * *
- The insights from the PEXIVAS Trial, a 10-year study, shows treatment for ANCA-associated vasculitis can become much more patient-friendly
* * *
A decade-spanning trial found that for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, two commo . . .
* * *
- The insights from the PEXIVAS Trial, a 10-year study, shows treatment for ANCA-associated vasculitis can become much more patient-friendly
* * *
A decade-spanning trial found that for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, two commo . . .